Trial Profile
A trial to evaluate the potential enhanced fibrinolytic and antiplatelet activity of dabigatran etexilate (DE) due to decreased thrombin levels in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation (NVAF)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2016
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- 22 Jul 2016 New trial record